<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960752</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0416</org_study_id>
    <secondary_id>NCI-2011-02363</secondary_id>
    <nct_id>NCT00960752</nct_id>
  </id_info>
  <brief_title>Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist</brief_title>
  <official_title>Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and&#xD;
      MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune&#xD;
      system against melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drug/Vaccines:&#xD;
&#xD;
      Resiquimod (R848) is designed to increase the production of antigen-specific T-cells, to&#xD;
      activate immune cells, and to increase T-cells going into the tumor, which may cause the&#xD;
      tumor cells to die.&#xD;
&#xD;
      gp100(g209-2M) and MAGE-3 are vaccines designed to stimulate immune cells, also called&#xD;
      T-cells, which may help the immune system to recognize and kill melanoma cells.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, and you have metastatic melanoma,&#xD;
      you will be assigned to Group 3. If you have had the melanoma removed and want to be treated&#xD;
      to try to keep it from coming back, you will be randomly assigned (as in the flip of a coin)&#xD;
      to Group 1 or 2.&#xD;
&#xD;
        -  If you are in Group 1, you will receive the vaccines gp100(g209-2M) and MAGE-3 and R848&#xD;
           for 8 weeks. After 8 weeks, if you have melanoma lesions, you will apply R848 to half of&#xD;
           the lesions on your body for 16 weeks.&#xD;
&#xD;
        -  If you are in Group 2, you will receive only the vaccines (gp100(g209-2M) and MAGE-3)&#xD;
           only for 8 weeks. After 8 weeks, if you have melanoma lesions, you will apply R848 to&#xD;
           half of the lesions on your body for 16 weeks.&#xD;
&#xD;
        -  If you are in Group 3, you will receive the vaccines gp100(g209-2M) and MAGE-3 and R848&#xD;
           for 8 weeks. After 8 weeks, if you have melanoma lesions, you will apply R848 to half of&#xD;
           the lesions on your body for 16 weeks.&#xD;
&#xD;
      After 8 weeks, if you no longer have melanoma lesions, you will have completed the study&#xD;
      treatment.&#xD;
&#xD;
      Study Drug/Vaccine Administration:&#xD;
&#xD;
      Once a week for 8 weeks, you will receive the vaccines, gp100(g209-2M) and MAGE-3,&#xD;
      intradermally (through a needle into your skin) and subcutaneously (through a needle under&#xD;
      your skin) at 2 separate sites in separate extremities. Half of each dose will be given one&#xD;
      way, and half given the other way. These vaccines will also be given on the same day. You&#xD;
      will receive a total of 4 injections each week.&#xD;
&#xD;
      If you are in Group 1, every time you have the vaccine injection, R848 will be applied as a&#xD;
      gel over the gp100(g209-2M) injection site. The R848 gel will be allowed to air dry for 30&#xD;
      minutes and then covered with a gauze dressing which remain on overnight.&#xD;
&#xD;
      After 8 weeks, for participants with melanoma lesions, 2 times a week for 16 weeks, you will&#xD;
      apply the R848 gel to half of the lesions on your body. You will be given written&#xD;
      instructions and a &quot;hands-on&quot; demonstration on how to apply the gel. You will also be given a&#xD;
      worksheet to help you with applying the gel.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      One day after your first dose of vaccine (Day 2), you will have a punch biopsy of the vaccine&#xD;
      injection site to check your immune system. A punch biopsy is when a hollow instrument that&#xD;
      is used to remove a small coin-shaped sample of tissue.&#xD;
&#xD;
      At Week 2, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs and weight.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests.&#xD;
&#xD;
        -  Blood (about 4 tablespoons) will be drawn to study your immune response to the vaccine&#xD;
           combinations.&#xD;
&#xD;
        -  You will have a punch biopsy of the injection site to check your immune system the day&#xD;
           after the vaccine is given.&#xD;
&#xD;
      Every 4 weeks, the following tests and procedures will be performed:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs and weight.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 1 teaspoon) will be drawn for routine tests.&#xD;
&#xD;
        -  Blood (about 4 tablespoons) will be drawn to study your immune response to the vaccine&#xD;
           combinations.&#xD;
&#xD;
      Every 8 weeks, for participants with metastatic disease, the following tests and procedures&#xD;
      will be performed:&#xD;
&#xD;
        -  You will have CT or PET/CT scans of the chest, abdomen, and pelvis to check the status&#xD;
           of the disease.&#xD;
&#xD;
        -  The tumors will be measured and photographed. Your private areas will be covered (as&#xD;
           much as possible), and a picture of your face will not be taken unless there are tumors&#xD;
           on your face.&#xD;
&#xD;
        -  If the doctor thinks it is necessary, the tumors will be measured by CT scan.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have an MRI/CT of the brain to check the&#xD;
           status of the disease.&#xD;
&#xD;
      The day after you first start the gel (Week 8), you will have 2 punch tumor biopsies to check&#xD;
      your immune system. One biopsy will be of a lesion with the R848 and one without, if it is&#xD;
      available. For participants without disease, the study will be completed and your follow-up&#xD;
      will be decided by your doctor.&#xD;
&#xD;
      At Week 0 (before vaccine is started), after treatment at Week 8 (+/- 1 week)., and Week 16&#xD;
      (+/- 1 week), white blood cells will be collected by leukapheresis to test for antibodies. If&#xD;
      you have the leukapheresis, blood (about 2 teaspoons) will be drawn as well. If you do not&#xD;
      have leukapheresis, blood (about 4 tablespoons) will be drawn instead.&#xD;
&#xD;
      The leukapheresis procedure is research-related and would not be performed as standard of&#xD;
      care if you were not on study. Blood for the leukapheresis will be taken through a needle in&#xD;
      a vein in one of your arms. A solution will be added to keep your blood from clotting while&#xD;
      it goes through the machine that collects and removes white blood cells from your blood. The&#xD;
      remaining blood is returned to you through a needle in a vein of your other arm. This is may&#xD;
      take up to 3-4 hours. Although several pints of blood will go through the machine, only about&#xD;
      1/2 a pint (1 cup) will be in the machine at any time. If you cannot have a needle in your&#xD;
      vein, this blood will be removed thorough a central venous catheter (CVC). A CVC is a sterile&#xD;
      flexible tube that will be placed into a large vein while you are under local anesthesia. You&#xD;
      will be given another informed consent document to sign, which describes the risks of the CVC&#xD;
      and the care involved.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will continue to receive treatment for up to 4 6 months, as long as you may benefit from&#xD;
      the study and are responding to the gel. You will be taken off study if the disease gets&#xD;
      worse or you experience any intolerable side effects. If you are in the group without&#xD;
      disease, you will not receive the study treatment.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      All three groups will be called 1 time a month for 12 months after coming off the study drugs&#xD;
      to check on the status of the disease.&#xD;
&#xD;
      This is an investigational study. The study drugs/vaccines gp100(g209-2M), MAGE-3, and R848&#xD;
      are not FDA approved or commercially available. At this time, they are only being used in&#xD;
      research.&#xD;
&#xD;
      Up to 71 participants will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2010</start_date>
  <completion_date type="Actual">July 20, 2020</completion_date>
  <primary_completion_date type="Actual">July 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone</measure>
    <time_frame>8 weeks</time_frame>
    <description>T-cell response to gp100(g209-2M) +/- MAGE3 measured at 8 weeks using a tetramer/multimer assay measured by flow cytometry. Based on the number of gp100(g209-2M) +/- MAGE3 T-cells measured, categorized as either immune responders or immune non-responders. T-cell response to the gp100(g209-2M) + /- MAGE3 peptide in each participant defined as ≥0.1% gp100(g209-2M) tetramer+ cells in the CD8+ T-cell population or ≥0.1% MAGE3 multimer cells in the CD4+ T-cell population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of Immune Cell Infiltration for pDCs, mDCs, and NK Cells in Tumor Biopsy Samples</measure>
    <time_frame>8 weeks</time_frame>
    <description>Differences determined in each of these parameters between the pretreatment and post-treatment samples for each of the biopsied lesions for each participant.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Group 1: gp100 and MAGE-3 + R848</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.&#xD;
After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: gp100 and MAGE-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.&#xD;
After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.&#xD;
After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gp100</intervention_name>
    <description>1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.</description>
    <arm_group_label>Group 1: gp100 and MAGE-3 + R848</arm_group_label>
    <arm_group_label>Group 2: gp100 and MAGE-3</arm_group_label>
    <arm_group_label>Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848</arm_group_label>
    <other_name>gp100 peptide</other_name>
    <other_name>g209-2M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R848 gel</intervention_name>
    <description>Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.</description>
    <arm_group_label>Group 1: gp100 and MAGE-3 + R848</arm_group_label>
    <arm_group_label>Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848</arm_group_label>
    <other_name>Resiquimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGE-3</intervention_name>
    <description>1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.</description>
    <arm_group_label>Group 1: gp100 and MAGE-3 + R848</arm_group_label>
    <arm_group_label>Group 2: gp100 and MAGE-3</arm_group_label>
    <arm_group_label>Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848</arm_group_label>
    <other_name>MAGE-3 peptide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HLA-A*0201 positive (to enable immunization with the HLA class I restricted&#xD;
             gp100(g209-2M) peptide). Stage IIB or IIC patients will be enrolled after review and&#xD;
             approval by the PI. (a tool to determine the projected survival at 5 years, like, but&#xD;
             not limited to, the nomogram at www.melanomaprognosis.org. If the projected survival&#xD;
             is less than 50% at 5 years, then the patient is considered for enrollment. This is&#xD;
             with the recognition that the adjuvant, if effective offers a significant impact in&#xD;
             that group of stage II patients.)&#xD;
&#xD;
          2. Patients &gt;/= 18 years old with histologically documented metastatic melanoma with a.&#xD;
             (Metastatic disease cohort) Measurable disease, stage IIIB, IIIC (in transit lesions&#xD;
             with or without nodal metastases) that includes lesions accessible for biopsies or IV&#xD;
             M1B b. (Adjuvant cohort) subjects who are NED and stage III or IV. This includes&#xD;
             patients with stage IV disease resected to NED. Stage IIB or IIC patients will be&#xD;
             enrolled after review and approval by the PI.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          4. At least 2 biopsiable easily accessible cutaneous and subcutaneous lesions in patients&#xD;
             in the metastatic disease cohort&#xD;
&#xD;
          5. White Blood Count (WBC) &gt;/= 3000/mm^3 (part 1 &amp; 2)&#xD;
&#xD;
          6. Platelet count &gt;/= 90,000/mm^3 (part 1 &amp; 2)&#xD;
&#xD;
          7. Serum alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) &lt;/= 3 X&#xD;
             upper limit of normal (ULN) (part 1 &amp; 2)&#xD;
&#xD;
          8. Total bilirubin &lt;/= 2 X ULN, except for patients with Gilbert's syndrome who must have&#xD;
             a total bilirubin less than 3.0 mg/dl Total bilirubin &lt;/= 2 X ULN, except for patients&#xD;
             with Gilbert's syndrome who must have a total bilirubin less than 3.0 mg/dl (part 1 &amp;&#xD;
             2)&#xD;
&#xD;
          9. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental&#xD;
             treatment being evaluated in this protocol depends on an intact immune system.&#xD;
             Patients who are HIV seropositive can have decreased immune competence and thus may be&#xD;
             less responsive to the experimental treatment and more susceptible to its toxicities.)&#xD;
&#xD;
         10. Negative pregnancy test for women of childbearing potential (WOCBP) A WOCBP has not&#xD;
             undergone a hysterectomy or who has not been naturally postmenopausal for at least 12&#xD;
             consecutive months (i.e., who has had menses at any time in the preceding 12&#xD;
             consecutive months)&#xD;
&#xD;
         11. Patients of both gender must practice a barrier method of birth control while&#xD;
             participating in this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active autoimmune disease requiring active therapy with any form of steroid or&#xD;
             immunosuppressive therapy or a documented history of any of the following:&#xD;
             inflammatory bowel disease; regional enteritis; systemic lupus erythematosis;&#xD;
             Sjogren's syndrome; inflammatory neurologic disorder such as multiple sclerosis; or&#xD;
             any immune mediated disease that can cause life-threatening symptoms or severe&#xD;
             organ/tissue damage in the opinion of the principle investigator.&#xD;
&#xD;
          2. Concurrent systemic or inhaled steroid therapy&#xD;
&#xD;
          3. Any form of active primary or secondary immunodeficiency&#xD;
&#xD;
          4. Prior malignancy except for the following: adequately treated basal cell or squamous&#xD;
             cell skin cancer, in-situ cervical cancer, thyroid cancer (except anaplastic) or any&#xD;
             cancer from which the patient has been disease-free for 2 years&#xD;
&#xD;
          5. History of immunization with gp100(g209-2M)&#xD;
&#xD;
          6. Active systemic infections requiring intravenous antibiotics&#xD;
&#xD;
          7. Women who are breastfeeding&#xD;
&#xD;
          8. Prior systemic therapy, radiation therapy or intracavitary surgery (intra-thoracic,&#xD;
             intra-abdominal or intracranial) within 28 days of starting study treatment.&#xD;
&#xD;
          9. Patients on chronic anticoagulation such as Aspirin, Plavix, or Coumadin who cannot&#xD;
             have anticoagulation held for procedures are not eligible due to the need for&#xD;
             leukapheresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Davies, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>July 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gp100 peptide</keyword>
  <keyword>MAGE-3 peptide</keyword>
  <keyword>R848</keyword>
  <keyword>Resiquimod</keyword>
  <keyword>Toll Like Receptor</keyword>
  <keyword>TLR</keyword>
  <keyword>T-cells</keyword>
  <keyword>Tumor</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Lesions</keyword>
  <keyword>Injection Site</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT00960752/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>47 participants enrolled on study, 1 participant screen failure, 1 participant stopped prematurely due to toxicity.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: GP100 and MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: GP100 and MAGE-3</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group 3-Metastatic Melanoma: GP100 + MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: GP100 and MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: GP100 and MAGE-3</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group 3-Metastatic Melanoma: GP100 + MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone</title>
        <description>T-cell response to gp100(g209-2M) +/- MAGE3 measured at 8 weeks using a tetramer/multimer assay measured by flow cytometry. Based on the number of gp100(g209-2M) +/- MAGE3 T-cells measured, categorized as either immune responders or immune non-responders. T-cell response to the gp100(g209-2M) + /- MAGE3 peptide in each participant defined as ≥0.1% gp100(g209-2M) tetramer+ cells in the CD8+ T-cell population or ≥0.1% MAGE3 multimer cells in the CD4+ T-cell population.</description>
        <time_frame>8 weeks</time_frame>
        <population>The original PI is no longer in the institution. Due to the absence of the original PI is no longer in the institution and the data is unavailable. The analysis for the primary outcome measure the comparison of immune responses of vaccine+R848 to vaccine alone is not available. All efforts were made to retrieve data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: GP100 and MAGE-3 + R848</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: GP100 and MAGE-3</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group 3-Metastatic Melanoma: GP100 + MAGE-3 + R848</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Immune Responses of Vaccine+R848 to Vaccine Alone</title>
          <description>T-cell response to gp100(g209-2M) +/- MAGE3 measured at 8 weeks using a tetramer/multimer assay measured by flow cytometry. Based on the number of gp100(g209-2M) +/- MAGE3 T-cells measured, categorized as either immune responders or immune non-responders. T-cell response to the gp100(g209-2M) + /- MAGE3 peptide in each participant defined as ≥0.1% gp100(g209-2M) tetramer+ cells in the CD8+ T-cell population or ≥0.1% MAGE3 multimer cells in the CD4+ T-cell population.</description>
          <population>The original PI is no longer in the institution. Due to the absence of the original PI is no longer in the institution and the data is unavailable. The analysis for the primary outcome measure the comparison of immune responses of vaccine+R848 to vaccine alone is not available. All efforts were made to retrieve data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Immune Cell Infiltration for pDCs, mDCs, and NK Cells in Tumor Biopsy Samples</title>
        <description>Differences determined in each of these parameters between the pretreatment and post-treatment samples for each of the biopsied lesions for each participant.</description>
        <time_frame>8 weeks</time_frame>
        <population>The original PI is no longer in the institution. Due to the absence of the original PI is no longer in the institution and the data is not available. The analysis for the secondary outcome measure the composite of Immune Cell Infiltration for pDCs, mDCs, and NK cells in Tumor Biopsy Samples data is unavailable .All efforts were made to retrieve data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: GP100 and MAGE-3 + R848</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: GP100 and MAGE-3</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group 3-Metastatic Melanoma: GP100 + MAGE-3 + R848</title>
            <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Immune Cell Infiltration for pDCs, mDCs, and NK Cells in Tumor Biopsy Samples</title>
          <description>Differences determined in each of these parameters between the pretreatment and post-treatment samples for each of the biopsied lesions for each participant.</description>
          <population>The original PI is no longer in the institution. Due to the absence of the original PI is no longer in the institution and the data is not available. The analysis for the secondary outcome measure the composite of Immune Cell Infiltration for pDCs, mDCs, and NK cells in Tumor Biopsy Samples data is unavailable .All efforts were made to retrieve data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>every 2 weeks through Week 4, then every 4 weeks during the vaccination treatment, up to 8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: GP100 and MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: GP100 and MAGE-3</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Group 3-Metastatic Melanoma: GP100 + MAGE-3 + R848</title>
          <description>1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Davis, PHD., Chair, Melanoma Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-3454</phone>
      <email>mdavies@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

